» Articles » PMID: 36727519

Network-Guided Multiomic Mapping of Aortic Valve Calcification

Overview
Date 2023 Feb 2
PMID 36727519
Authors
Affiliations
Soon will be listed here.
Abstract

Despite devastating clinical sequelae of calcific aortic valve disease that range from left ventricular remodeling to arrhythmias, heart failure, and early death, the molecular insights into disease initiation and progression are limited and pharmacotherapies remain unavailable. The pathobiology of calcific aortic valve disease is complex and comprehensive studies are challenging valvular calcification is heterogeneous and occurs preferentially on the aortic surface, along a fibrocalcific spectrum. Here, we review efforts to study (epi-)genomic, transcriptomic, proteomic, and metabolomic aspects of aortic valve calcification in combination with network medicine-/systems biology-based strategies to integrate multilayered omics datasets and prioritize druggable targets for experimental validation studies. Ultimately, such holistic approach efforts may open therapeutic avenues that go beyond invasive and costly valve replacement therapy.

Citing Articles

Calcific aortic stenosis: omics-based target discovery and therapy development.

Blaser M, Back M, Luscher T, Aikawa E Eur Heart J. 2024; 46(7):620-634.

PMID: 39656785 PMC: 11825147. DOI: 10.1093/eurheartj/ehae829.


Immunotherapy in the Context of Aortic Valve Diseases.

Bartoli-Leonard F, Pennel T, Caputo M Cardiovasc Drugs Ther. 2024; 38(6):1173-1185.

PMID: 39017904 PMC: 11680629. DOI: 10.1007/s10557-024-07608-7.


Insights into calcific aortic valve stenosis: a comprehensive overview of the disease and advancing treatment strategies.

Jain H, Goyal A, Khan A, Khan N, Jain J, Chopra S Ann Med Surg (Lond). 2024; 86(6):3577-3590.

PMID: 38846838 PMC: 11152847. DOI: 10.1097/MS9.0000000000002106.


Enhancing aortic valve drug delivery with PAR2-targeting magnetic nano-cargoes for calcification alleviation.

Chen J, Ren T, Xie L, Hu H, Li X, Maitusong M Nat Commun. 2024; 15(1):557.

PMID: 38228638 PMC: 10792006. DOI: 10.1038/s41467-024-44726-0.

References
1.
Liao Y, Liu C, Xiong T, Zhao M, Zheng W, Feng Y . Metabolic Modulation and Potential Biomarkers of the Prognosis Identification for Severe Aortic Stenosis after TAVR by a Metabolomics Study. Cardiol Res Pract. 2020; 2020:3946913. PMC: 7649585. DOI: 10.1155/2020/3946913. View

2.
Garg V, Muth A, Ransom J, Schluterman M, Barnes R, King I . Mutations in NOTCH1 cause aortic valve disease. Nature. 2005; 437(7056):270-4. DOI: 10.1038/nature03940. View

3.
Mourino-Alvarez L, Iloro I, de la Cuesta F, Azkargorta M, Sastre-Oliva T, Escobes I . MALDI-Imaging Mass Spectrometry: a step forward in the anatomopathological characterization of stenotic aortic valve tissue. Sci Rep. 2016; 6:27106. PMC: 4891820. DOI: 10.1038/srep27106. View

4.
Denisenko E, Guo B, Jones M, Hou R, de Kock L, Lassmann T . Systematic assessment of tissue dissociation and storage biases in single-cell and single-nucleus RNA-seq workflows. Genome Biol. 2020; 21(1):130. PMC: 7265231. DOI: 10.1186/s13059-020-02048-6. View

5.
Aikawa E, Hutcheson J . The Developmental Origin of Calcific Aortic Stenosis. N Engl J Med. 2022; 386(14):1372-1374. DOI: 10.1056/NEJMcibr2200439. View